DSIP

DSIP is an endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) implicated in the regulation of sleep-wake cycling and named for its association with delta-wave (slow-wave) sleep. It was isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically induced slow-wave sleep. It is produced in the hypothalamus and crosses the blood-brain barrier readily.

The mechanism is multi-pathway and incompletely characterised: GABA potentiation, NMDA receptor antagonism, HPA-axis and cortisol modulation, influence on serotonin and melatonin release, stimulation of LH and GH release, and an opioid-system interaction reversible by naloxone. The GABAergic component underlies the stated over-sedation risk with other GABAergic agents; the opioid interaction underlies the analgesic and withdrawal-support signals.

Pharmacokinetics: plasma half-life is approximately 7 to 15 minutes owing to rapid enzymatic degradation, with in vivo complexing to carrier proteins proposed to extend functional duration. DSIP is degraded in blood by aminopeptidases, which is the basis of the existing exclusion for ACE inhibitors such as captopril.

The evidence base is dated. Most clinical work is from the 1980s in small samples; results are mixed, and the one double-blind trial in chronic insomniacs (Schneider-Helmert, European Neurology, 1984) found only weak effects and concluded short-term treatment is "not likely to be of major therapeutic benefit". No modern randomised controlled trials exist. The peptide sits in the promising-mechanism, limited-human-evidence category.

Regulatory: not FDA approved; classified in 2024 as an FDA Category 2 bulk drug substance, not eligible for compounding; available as a research chemical.

Presentation is a lyophilised vial (10 mg in the standard protocol; 5 mg vials are also common) reconstituted with bacteriostatic water for subcutaneous administration 30 to 60 minutes before sleep.

DSIP promotes sleep and dampens stress through several partly confirmed pathways.

GABA potentiation. DSIP enhances GABAergic transmission, the principal inhibitory system in the CNS, quieting cortical activity in a manner mechanistically adjacent to benzodiazepines but without the reported dependency or cognitive impairment. This is the substrate for the additive-sedation caution with other GABAergic agents.

NMDA antagonism. DSIP blocks NMDA receptors, reducing excitatory glutamatergic signalling. Combined with GABA enhancement, the net effect is a shift of the excitation-inhibition balance towards a sleep-permissive state.

HPA-axis modulation. DSIP reduces cortisol when elevated and normalises the stress response via the hypothalamic-pituitary-adrenal axis. In animal work it showed stress-protective properties under experimental hypoxia (Khvatova et al., Peptides, 2003).

Circadian support. DSIP influences serotonin and melatonin release, aligning sleep with endogenous rhythm rather than imposing sedation.

Endocrine effects. DSIP stimulates luteinising hormone and growth hormone release. Increased GH during slow-wave sleep supports recovery, muscle repair and fat metabolism; the LH effect has a theoretical bearing on testosterone but is untested in controlled human trials.

Opioid interaction. DSIP acts at opioid receptors, contributing to analgesia. In animal studies DSIP, like morphine, induced slow-wave sleep through bulbo-mesencephalo-thalamic pathways, and the effect was reversed by naloxone. It nonetheless operates through a distinct pathway from opioid drugs and produces neither addiction nor respiratory depression.

Metabolism. Degradation is by plasma aminopeptidases, with a half-life of approximately 7 to 15 minutes; carrier-protein complexing is the proposed explanation for a functional duration longer than the plasma figure implies. Agents that interfere with aminopeptidase activity, such as captopril, may alter clearance.

Schneider-Helmert and Schoenenberger (Neuropsychobiology, 1983) noted no sedation in the classic pharmacological sense, consistent with a rhythm-enhancing rather than sedative model.

Primary application is sleep: reduced sleep latency, increased total sleep duration, sleep induction in insomnia and circadian disruption, and increased slow-wave sleep without REM suppression. Schneider-Helmert and Schoenenberger (Neuropsychobiology, 1983) recorded a 59% increase in total sleep time within a 130-minute window in six healthy volunteers, with improved onset and efficiency the following night. In 16 chronic insomniacs over 5 nights (European Neurology, 1984) sleep efficiency and latency improved but the effect was weak; an open series of 7 severe insomniacs saw sleep normalised in 6 of 7 after 10 injections, with benefit persisting 3 to 7 months, though without placebo control.

Stress: HPA-axis modulation with reduction of elevated cortisol; significantly increased resistance to acute emotional stress; stress-protective potency under experimental hypoxia in animals.

Analgesia: reduced pain severity and improved mood in chronic, pronounced pain (Larbig et al., European Neurology, 1984), with some patients reducing analgesic use.

Withdrawal: in 107 patients detoxing from alcohol (47) or opioids (60) given intravenous DSIP at 25 nmol/kg, symptoms alleviated in 97% of opiate-dependent and 87% of alcohol-dependent patients (Dick et al., European Neurology, 1984).

Endocrine: stimulation of GH and LH release; GH support via increased slow-wave sleep.

Neurological: powerful antioxidant activity; anti-epileptic properties; improved spatial memory; reduction in depression; improved survival after cerebral ischaemia. In a rat focal stroke model, intranasal DSIP at 120 mcg/kg for 8 days significantly improved motor recovery without reducing infarct size (Solnyshkova et al., Molecules, 2021). A 2024 fusion peptide (DSIP-CBBBP) outperformed native DSIP on neurotransmitter imbalance in a PCPA-induced insomnia mouse model (Frontiers in Pharmacology, 2024).

Cardiovascular: potential correction of arrhythmia; frequent reduction in blood pressure; improved blood flow via direct cardiac action.

Oncological: reduced risk of tumour growth; enhanced chemotherapeutic efficacy with reduced adverse effects. Ophthalmic: improved vision in diabetic eye complications.

Onset is 10 to 30 minutes after subcutaneous injection. Reports range from an immediate sense of sleep pressure, consistent with the immediate sleep pressure noted in Schneider-Helmert and Schoenenberger (Neuropsychobiology, 1983), to a gradual settling. There is no sedation in the classic pharmacological sense; the effect is on sleep architecture rather than forced unconsciousness.

First night: variable. Some users report faster onset and heightened sleep pressure, others no discernible effect. A single night is not diagnostic.

Nights 5 to 7 of consecutive dosing: progressive improvement in continuity and depth. Fewer nocturnal awakenings is the most consistent user report, followed by improved restedness on waking without residual grogginess, and increased dream vividness, recall and lucid dreaming.

Longer term: in the open case series, 6 of 7 severe insomniacs had sleep normalised after 10 injections with benefit persisting 3 to 7 months, plus improved daytime mood and performance. The absence of placebo control means expectation effects cannot be excluded; the double-blind chronic insomnia trial found only weak effects.

Inter-individual variation is substantial and mirrors the mixed clinical literature.

Dose sensitivity: users report that higher doses paradoxically disrupt sleep or produce grogginess and extended sleepiness into the following day. The consistent recommendation is to start low and titrate. At standard doses, no next-day sedation is expected.

Adaptation: some users report a temporary decline in sleep quality on cessation after prolonged nightly use. This is distinct from chemical dependency, none of which was seen in clinical studies, but it is the rationale for cycling.

Non-response is frequently attributable to an inadequate sleep window (4 to 5 hours) or nocturnal hypoglycaemia from undereating, particularly alongside GLP-1 agonists. DSIP does not compensate for either.

Reconstitution. Standard presentation is a 10 mg vial with 2 mL bacteriostatic water, giving 5 mg/mL, or 50 mcg per insulin unit. Equivalently, 500 mcg per 10 units and 4 units for 200 mcg. Draws: 100 mcg = 2 units, 200 mcg = 4 units, 300 mcg = 6 units. A 5 mg vial reconstituted with 2.5 mL gives 20 mcg per unit (100 mcg = 5 units, 200 mcg = 10 units). Add diluent down the vial wall and swirl; do not shake.

Standard protocol. 100 to 300 mcg subcutaneously once daily, 30 to 60 minutes before target sleep time, for 5 to 10 consecutive nights, then evaluate. Titrate from the floor; users report paradoxical sleep disruption and next-day grogginess at higher doses.

Body-weight tiers. Under 150 lbs: 100 to 150 mcg nightly. 150 to 200 lbs: 150 to 250 mcg. Over 200 lbs: 200 to 300 mcg.

Application tiers. General sleep optimisation: 100 to 200 mcg. Stress-related sleep disturbance: 200 to 300 mcg. GH-secretagogue sleep disruption: 100 to 200 mcg. Shift work: 200 to 300 mcg before target sleep time irrespective of clock time.

Timing. 30 to 60 minutes pre-sleep. Administration 2 to 3 hours before bed is reported as less effective. Onset 10 to 30 minutes.

Cycling. No cycling protocol exists in published research. On the theoretical concern of receptor adaptation, common practice is 5 to 10 consecutive nights then a break, or 3 to 5 nights per week. Loss of effect after prolonged daily use is managed with a 1 to 2 week washout. Some earlier practice ran 8 to 12 week cycles with a 4 to 8 week washout and titration from 100 mcg in weekly 100 mcg steps; the current standard is the shorter, lower-dose pattern above.

Evidence basis. The practical protocols are clinical practice patterns, not dose-finding data; no published dose-finding studies exist for subcutaneous DSIP. Clinical studies used 25 nmol/kg intravenously (Schneider-Helmert; Dick), approximately 75 mcg for a 180 lb person, and the rat stroke model used 120 mcg/kg intranasally for 8 days. The subcutaneous range therefore sits above the studied intravenous exposure, which is a further argument for starting low.

DSIP was isolated in 1977 by Schoenenberger and Monnier from cerebral venous blood of rabbits during electrically induced slow-wave sleep. The nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is hypothalamic in origin, crosses the blood-brain barrier readily, and has a plasma half-life of approximately 7 to 15 minutes due to aminopeptidase degradation, possibly extended in vivo by carrier-protein complexing.

Mechanistically it potentiates GABAergic transmission, antagonises NMDA receptors to reduce glutamatergic drive, modulates the HPA axis and lowers elevated cortisol, influences serotonin and melatonin release, stimulates GH and LH release, and interacts with opioid receptors — its slow-wave-sleep induction via bulbo-mesencephalo-thalamic pathways in animal models was naloxone-reversible. Not all pathways are confirmed.

Human evidence is almost entirely 1980s and small. Schneider-Helmert and Schoenenberger (Neuropsychobiology, 1983): double-blind crossover, six healthy volunteers, 25 nmol/kg IV; total sleep time increased 59% within 130 minutes, with reduced onset latency and improved efficiency the following night and no classic sedation. Schneider-Helmert (Eur Neurol, 1984): double-blind, 16 chronic insomniacs, 5 nights; higher sleep efficiency and shorter latency but weak effects, concluding short-term DSIP treatment of chronic insomnia is "not likely to be of major therapeutic benefit". Schneider-Helmert (Eur Neurol, 1984), open series: 7 severe insomniacs, 10 injections; sleep normalised in 6 of 7 with benefit persisting 3 to 7 months and improved daytime mood and performance — uncontrolled, so expectation effects are likely.

Dick et al. (Eur Neurol, 1984): 107 patients (47 alcohol, 60 opioid) at 25 nmol/kg IV; withdrawal symptoms alleviated in 97% of opiate-dependent and 87% of alcohol-dependent patients, headaches in a few. Larbig et al. (Eur Neurol, 1984): chronic pronounced pain; reduced pain, improved mood, some analgesic reduction.

Preclinical: Solnyshkova et al. (Molecules, 2021), intranasal 120 mcg/kg for 8 days in a rat focal stroke model, significantly improved motor recovery without reduced infarct size. Khvatova et al. (Peptides, 2003) reported stress-protective activity under experimental hypoxia. Zhang et al. (Front Pharmacol, 2024) found a DSIP-CBBBP fusion peptide restored neurotransmitter balance better than native DSIP in a PCPA-induced insomnia mouse model.

No modern RCTs and no dose-finding studies exist for subcutaneous protocols. Regulatory status: not FDA approved; FDA Category 2 bulk drug substance as of 2024.